Combined use of trimethylamine N-oxide with BNP for risk stratification in heart failure with preserved ejection fraction: findings from the DIAMONDHFpEF study
Restricted accessResearch articleFirst published online December, 2020
Combined use of trimethylamine N-oxide with BNP for risk stratification in heart failure with preserved ejection fraction: findings from the DIAMONDHFpEF study
Wang Z, Bergeron N, Levison BS, et al. Impact of chronic dietary red meat, white meat, or non-meat protein on trimethylamine N-oxide metabolism and renal excretion in healthy men and women. Eur Heart J. Epub ahead of print 12 December 2018. DOI: 10.1093/eurheartj/ehy799.
2.
Cassambai S, Salzano A, Yazaki Y, et al. Impact of acute choline loading on circulating trimethylamine N-oxide (TMAO) levels. Eur J Prev Cardiol. 2019; 26: 1899–1902.
3.
Suzuki T, Yazaki Y, Voors AA, et al. Association with outcomes and response to treatment of trimethylamine N-oxide in heart failure (from BIOSTAT-CHF). Eur J Heart Fail 2018; 21: 877–886.
4.
TangWHWangZFanY, et al.Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: refining the gut hypothesis. J Am Coll Cardiol2014; 64: 1908–1914.
5.
SuzukiTHeaneyLMBhandariSS, et al.Trimethylamine N-oxide and prognosis in acute heart failure. Heart2016; 102: 841–848.
6.
Yazaki Y, Salzano A, Nelson PC, et al. Geographical location affects the levels and association of trimethylamine N-oxide with heart failure mortality in BIOSTAT-CHF: a post-hoc analysis. Eur J Heart Fail 2019; in press.
7.
Kanagala P, Cheng ASH, Singh A, et al. Relationship between focal and diffuse fibrosis assessed by CMR and clinical outcomes in heart failure with preserved ejection fraction. JACC Cardiovasc Imaging. Epub ahead of print 13 February 2019. DOI: 10.1016/j.jcmg.2018.11.031.
8.
HeaneyLMJonesDJMbasuRJ, et al.High mass accuracy assay for trimethylamine N-oxide using stable-isotope dilution with liquid chromatography coupled to orthogonal acceleration time of flight mass spectrometry with multiple reaction monitoring. Anal Bioanal Chem2016; 408: 797–804.
9.
PonikowskiPVoorsAAAnkerSD, et al.2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail2016; 18: 891–975.
10.
SchuettKKleberMEScharnaglH, et al.Trimethylamine-N-oxide and heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol2017; 70: 3202–3204.
11.
TangWHWangZShresthaK, et al.Intestinal microbiota-dependent phosphatidylcholine metabolites, diastolic dysfunction, and adverse clinical outcomes in chronic systolic heart failure. J Cardiac Fail2015; 21: 91–96.
12.
O’NealWTSandesaraPBSamman-TahhanA, et al.Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction. Eur J Prev Cardiol2017; 24: 1212–1219.
13.
SatoTYoshihisaAKannoY, et al.Cardiopulmonary exercise testing as prognostic indicators: comparisons among heart failure patients with reduced, mid-range and preserved ejection fraction. Eur J Prev Cardiol2017; 24: 1979–1987.
14.
SalzanoAMarraAMD’AssanteR, et al.Biomarkers and imaging: complementary or subtractive?Heart Fail Clin2019; 15: 321–331.
